Associate Director, Clinical Biomarker Development

Revolution Medicines•Redwood City, CA

2d•Hybrid

About The Position

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Associate Director in Clinical Biomarker Development team, within Translational Medicine will play a key role in the design, execution, and interpretation of clinical biomarker strategies across Revolution Medicine’s oncology pipeline.

Requirements

Ph.D in cancer biology, cell/molecular biology, genomics or equivalent is required.
3+ years of clinical biomarker and/or assay development experience in industry is required.
Experience and track-record of the development, validation, and clinical implementation of biomarker readouts is required.
Experience of working with Contract Research Organizations to deliver biomarker readouts is required.
Excellent scientific and business communication skills, strong interpersonal/collaboration skills and planning skills.
Ability to think critically and creatively and be able to work independently to determine appropriate resources for resolution of problems.
Ability to multi-task and thrive in a fast-paced innovative environment.

Nice To Haves

Experience with targeted oncology therapies or RAS/MAPK pathway biology.
Biological understanding of pancreatic, non-small cell lung and/or colorectal cancers is preferred.
Familiarity with biomarker platforms such as genomic, transcriptomic and proteomic assays.
Familiarity with analytical software and analytical capabilities for integrating clinical and biomarker datasets.

Responsibilities

Develop and maintain translational and clinical biomarker strategies to support portfolio assets from phase 1 to phase 3 studies.
Support the development of biomarker related aspects of the trial design, including assay development, patient sample acquisition, study protocols, clinical biomarker plans, and other regulatory documents.
Participate in cross-functional teams such as clinical working groups and clinical study execution teams.
Work with internal translational groups, contract research organizations and collaborators to develop and validate assays for clinical use.
Manage outsourcing to CROs, oversee development of the scope of work, contracting, budgets, and timelines.
Collaborate with Clinical Bioinformatics and Cancer Genomics to support analysis of biomarker readouts, presenting outputs to internal and external stakeholders.